Evidence map›Paper›PMID 21867408›Full record

ArticleAIDS research and human retroviruses2012

Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population.

Jennifer Serwanga, Susan Mugaba, Edward Pimego, Bridget Nanteza, Fred Lyagoba, Susan Nakubulwa, Laura Heath, Rebecca N Nsubuga, Nicaise Ndembi, Frances Gotch and 1 more

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Jennifer SerwangaMRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. jennifer.serwanga@mrcuganda.org
Susan Mugaba
Edward Pimego
Bridget Nanteza
Fred Lyagoba
Susan Nakubulwa
Laura Heath
Rebecca N Nsubuga
Nicaise Ndembi
Frances Gotch
Pontiano Kaleebu
Uganda Virus Research Institute · UGLondon School of Hygiene & Tropical Medicine · GBUniversity of Washington · US

Funding

Medical Research Council G0501957Medical Research Council MC_U950081327
6 · The paper itself

Abstract

Reagents for evaluating non-clade B HIV-specific T cell responses are uncommon. Peptides based on highly conserved HIV-1 consensus group M sequences that are phylogenetically closer to most circulating strains may provide potential alternative reagents in populations with diverse infections, and may be relevant for vaccine design. Recognition of such reagents in clade A1-and D-infected populations has not been previously evaluated. Interferon (IFN)-γ ELISpot assay was used to evaluate T cell recognition of Gag and Nef peptides based on consensus group M sequences in 50 treatment-naive adults predominantly infected with HIV-1 clades A1 and D. Gag-induced T cell responses were correlated with gag sequence diversity. Infecting clades were determined from gag sequences for 45 of the 50 subjects as 40% clade A1 (18/45), 45% clade D (20/45), 2% clade C (1/45), 2% A1/C recombinant (1/45), 2% A1/D (1/45), 7% CRF10_CD (3/45), and 2% U (unclassifiable) (1/45). The mean genetic divergence and diversity of clade A and D gag region compared to group M consensus sequences at synonymous and nonsynonymous nucleotide and amino acid levels were not always significant. Gag peptides were targeted at significantly higher frequency [88% (44/50)] than Nef [64% (32/50)]; p=0.014, although their mean IFN-γ magnitudes were comparable ([3703 (95% CI 2567-4839)] vs. [2120 (95% CI 478-3762)]), respectively. Measurable virus-induced IFN-γ responses were detected in 96% (48/50) individuals, primarily targeting the more conserved Gag p24 and Nef central core regions. Use of these reagents to screen for HIV-specific IFN-γ responses may mitigate the challenge of viral diversity; although this targeting is apparently biased toward a few highly conserved epitopes.

Indexed as

AdultAIDS VaccinesBlack PeopleFemalegag Gene Products, Human Immunodeficiency VirusHIV-1HIV SeropositivityHumansImmunodominant EpitopesInterferon-gammaInterferon gamma ReceptorMalenef Gene Products, Human Immunodeficiency VirusReceptors, InterferonT-LymphocytesUgandaAIDS Vaccinesgag Gene Products, Human Immunodeficiency VirusImmunodominant EpitopesInterferon-gammaInterferon gamma Receptornef Gene Products, Human Immunodeficiency VirusReceptors, Interferon

Identifiers

PMID21867408
PMCPMC3316116
OpenAlexW1997070703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.